For locally advanced (stage II–III) lung cancer, Chinese oncology teams helped define the modern sequence: 2–4 cycles of PD-1 immunotherapy (with or without chemotherapy) to shrink the tumour first, then a minimally invasive resection on a down-staged, easier-to-operate field. China's domestic PD-1 agents made this protocol affordable as well as effective.
What it treats & who qualifies
- Resectable stage II–III non-small cell lung cancer where downstaging improves the operative field.
- Tumours with high PD-L1 expression or other biomarkers predicting immunotherapy response.
- Medically fit patients able to commit to a 3–5 month treatment window.
- Not for: oncogene-addicted cancers (EGFR/ALK driven) where targeted therapy — also strong in China — replaces immunotherapy.
Why patients travel to China for this
- China ran and published some of the landmark neoadjuvant immunotherapy trials in lung cancer; major pathological response rates reported by Chinese series are at the international frontier.
- Domestic PD-1 inhibitors (camrelizumab, sintilimab, tislelizumab, toripalimab) cost a fraction of Western list prices — often US$2,000–5,000 per cycle self-pay versus US$12,000–15,000 in the US.
- The complete pathway — medical oncology, surgery, pathology — is delivered inside one hospital system, avoiding the fragmented handovers that break this protocol elsewhere.
Treatment options, compared
| Option | Best suited for | What it means in practice |
|---|
| Neoadjuvant immunotherapy + chemotherapy, then VATS resection | The flagship pathway | Chinese-led trials helped define it; domestic agents make it affordable. |
|---|
| Neoadjuvant immunotherapy alone, then surgery | Selected PD-L1-high tumours | Lighter toxicity; used in specific trial protocols. |
|---|
| Upfront surgery, then adjuvant immunotherapy | Small stage II tumours | Chosen when delay is riskier than downstaging benefit. |
|---|
The procedure, step by step
- Biopsy and PD-L1 testing confirm diagnosis; PET-CT and brain MRI complete staging.
- 2–4 cycles of PD-1 (± chemotherapy) run on a 3-week cadence, with CT response assessment after cycle 2.
- Once re-staging shows resectable disease, surgery is scheduled — single-port or multi-port VATS depending on anatomy.
- Post-operative pathology (MPR assessment) guides adjuvant therapy decisions.
- Adjuvant immunotherapy continues up to a year, coordinated with your home oncologist.
Cost, hospital stay & recovery
| Typical China cost (reference only) | US$12,000–28,000 for the complete journey (neoadjuvant cycles + surgery), depending on agent choice and cycle count |
|---|
| Typical in-hospital stay | Neoadjuvant phase: outpatient; surgical admission 4–6 days |
|---|
| Return-to-travel timeline | Treatment window 3–5 months end-to-end; patients usually stay in China 6–10 weeks across the whole pathway |
|---|
Costs are indicative ranges for international self-pay patients at major Chinese hospitals; final quotes depend on the hospital, implant/medication choice and case complexity. WellVoyage locks a written all-in quote before you commit.
Recovery, week by week
- Weeks 1–9: Cycles 1–3 on a 21-day cadence; response CT after cycle 2; most side effects manageable as an outpatient.
- Week 10–12: Re-staging, surgical booking, minimally invasive resection.
- Week 13–17: Hospital stay 4–6 days, then recovery; pathology review sets the adjuvant plan.
- Month 4–12: Adjuvant immunotherapy up to a year, largely manageable at home with the Chinese records.
Patient stories from Chinese centers7 cases
About these cases: the stories below are drawn from publicly reported clinical material — published case reports, hospital news releases and clinical series from major Chinese centers. Names and identifying details have been changed or omitted. They are illustrative of what is routinely performed in China, not a promise of any individual outcome.
A 57-year-old man from the United States with stage IIIA lung cancer
A tumour too large for immediate surgery. Two cycles of neoadjuvant chemo-immunotherapy in Shanghai shrank it by 60%; VATS lobectomy followed, and pathology found almost no viable tumour left.
Source: Published Chinese neoadjuvant cohorts; anonymised.
A 60-year-old man from the Netherlands with locally advanced NSCLC
His Dutch team planned chemoradiation alone. He sought a second opinion and a Chinese multidisciplinary board offered the conversion-to-surgery pathway — neoadjuvant immunotherapy, then a minimally invasive resection.
Source: Published Chinese conversion-surgery series; anonymised.
A 55-year-old woman from Australia with a borderline-resectable tumour
One centimetre of growth made the difference between resectable and not. Neoadjuvant therapy pulled her firmly into the resectable column; the operation happened fourteen weeks after her first email.
Source: Hospital-reported international case; anonymised.
A 58-year-old man from Jordan with a Pancoast-region tumour
Shoulder pain misdiagnosed as arthritis for six months. Neoadjuvant chemo-immunotherapy downstaged the tumour away from the chest wall, and a minimally invasive resection completed the treatment.
Source: Public clinical reports; anonymised.
A 52-year-old woman from Morocco with N2 disease
Mediastinal nodes made her case complex. A Chinese tumour board sequenced immunotherapy, then surgery, then adjuvant therapy — a plan her Casablanca oncologist now co-manages by email.
Source: Published Chinese multimodal NSCLC series; anonymised.
A 49-year-old man from Vietnam with a large central tumour
Sleeve resection after neoadjuvant response preserved his lobe. Pathology staged him down from IIIA to ypT2N1 — a result his family had been told to abandon hope of.
Source: Hospital-reported case; anonymised.
A 63-year-old woman from Kazakhstan with PET-complete response — almost
Imaging suggested the tumour had melted; surgery found microscopic residue. That residual is why she chose a team that operates even after beautiful scans — the microscope sees what PET cannot.
Source: Public clinical reports; anonymised.
Frequently asked questions
Which PD-1 agent will I get?
Your Chinese oncologist selects from both imported and domestic agents based on PD-L1 expression and your budget; domestic agents are why this pathway is affordable — WellVoyage presents the options with written prices before anything is administered.
Do I stay in China for the whole treatment?
Not necessarily. A common pattern is 2 cycles in China, surgery, then continuing adjuvant dosing at home under your local oncologist using the Chinese records — WellVoyage prepares the translated handover pack.
Medical disclaimer: WellVoyage is a medical-travel coordination service, not a medical provider. This guide is general information, not medical advice; treatment decisions rest with your treating physicians. Patient stories are drawn from publicly reported, anonymised material and do not promise any individual outcome. Cost figures are reference ranges; the binding price is your written quote. Hospitals and doctors named on this site are independent third parties, not our partners. In an emergency, contact your local emergency services immediately.